Drugs · acquisition-cost intelligence
Quetiapine Extended Release
quetiapine· ingredient quetiapine· QUETIAPINE 150 mg/1; QUETIAPINE 200 mg/1; QUETIAPINE 300 mg/1; QUETIAPINE 400 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.22013
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-10-222026-05-20
Same-ingredient options by acquisition cost
Other quetiapine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Quetiapine fumarate | $0.05260 | −$0.16750 |
| Quetiapine Extended Release | $0.10996 | −$0.11020 |
| SEROQUEL | $9.18 | +$8.96 |
Medicare Part D coverage · CY2026
On 305 plan formularies · typical tier 2
Prior auth 31% · Step therapy 0% · Quantity limit 77% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.